Patient selection criteria.

<div><p>Background</p><p>Risk factors and comorbidities can complicate management of non-valvular atrial fibrillation. We describe and compare real-world safety and effectiveness of direct oral anticoagulants (DOACs; apixaban, rivaroxaban, dabigatran) and vitamin K antagonist...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Gregory Y. H. Lip (7429799) (author)
مؤلفون آخرون:	Robert Benamouzig (4392523) (author), Anne-Céline Martin (9848645) (author), Giancarlo Pesce (184046) (author), Gaelle Gusto (701016) (author), Nadia Quignot (104032) (author), Artak Khachatryan (10168891) (author), Feng Dai (113825) (author), Fouad Sedjelmaci (20234583) (author), Jose Chaves (20234586) (author), Rupesh Subash (20234589) (author), Ruth Mokgokong (8284968) (author)
منشور في:	2025
الموضوعات:	Medicine Cell Biology Genetics Biotechnology Developmental Biology Marine Biology Mental Health xlink "> anticoagulant vitamin k antagonists valvular atrial fibrillation receiving concomitant medications cohort study based na &# 239 xlink "> doacs snds )</ p direct oral anticoagulants bled ≥ 3 systemic embolism risk vkas among subgroups gastrointestinal bleeding bleed subgroups evaluated (< apixaban versus rivaroxaban systemic embolism oral anticoagulants subgroups (< &# 8805 high risk matched subgroups key subgroups following subgroups world safety versus dabigatran utilizing data propensity score p </ national quasi major bleeding improved safety gastrointestinal bleeding december 2019 complicate management compare real comparative safety >≤ 0 >< 0 75 years
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Patient selection criteria.

مواد مشابهة